Getty Images— Excision reported positive safety and biodistribution data to 48 weeks in the first-in-human Phase 1/2 clinical evaluation of EBT-101
— No serious adverse events or dose-limiting toxicities were seen in any trial participant
— EBT-101 was detected in blood in all participants
Read the full press release here.
Source : Excision BioTherapeutics Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.